The gut microbiome has been implicated in more than 25 diseases, such as Irritable Bowel Syndrome, autism, diabetes, and Parkinson’s, but there is no easy way for most drug companies determine if gut flora causes these diseases. Big Pharma often lack the microbiology know-how to leverage microbiome science for drug discovery, leaving a void for smaller biotech companies to fill. More than 400 microbiome startups have launched in the past 5 years, but most of them only use Western population data. They are missing data on the Asia gut microbiome and undiscovered probiotic strains.
We use carefully selected live bacteria to formulate patented live bio-therapeutics and initiate US-based investigational new drug discovery (IND) human trials. We license or co-develop these discovered drug candidates with large pharma partners, achieving early-stage monetization around Phase 1 human clinical trials. Our technology platform can validate multiple drug targets in ¼ the time of traditional drug discovery with 10x the predicted safety profile.
Read more on their website: http://www.asiabiome.com